Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma Patients Clear all
Completed Not applicable Interventional

Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients

NCT02913092
View directory record Official record
Conditions
Asthma
Interventions
Electronic sensor and OW education
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jun 26, 2026, 4:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

NCT01589198
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Not applicable Interventional

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

NCT01039324
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions
Reports, Reports and Notices, Usual care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
8,422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

NCT01836471
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544
View directory record Official record
Conditions
Asthma
Interventions
anti-IL-4 monoclonal antibody (pascolizumab)
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Los Angeles, California • Mission Viejo, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

NCT01581177
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jun 26, 2026, 4:12 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

NCT01290887
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

NCT00452348
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Jun 26, 2026, 4:12 AM EDT
Recruiting Phase 2 Interventional

Escitalopram in Asthma Patients With Frequent Exacerbation

NCT06216535
View directory record Official record
Conditions
Asthma
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Jun 26, 2026, 4:12 AM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

NCT00403637
View directory record Official record
Conditions
Asthma
Interventions
indacaterol maleate
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

Pneumococcal Vaccines in Patients With Asthma

NCT03260790
View directory record Official record
Conditions
Asthma
Interventions
PCV13, PPSV23
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jun 26, 2026, 4:12 AM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603
View directory record Official record
Conditions
Persistent Asthma
Interventions
QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

NCT00174720
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

NCT02995733
View directory record Official record
Conditions
Asthma
Interventions
PARTICS using QVAR
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jun 26, 2026, 4:12 AM EDT
Completed No phase listed Observational

Observational Study of Obstructive Lung Disease (NOVELTY)

NCT02760329
View directory record Official record
Conditions
Asthma, COPD, Chronic Obstructive Pulmonary Disease
Interventions
Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
40
States / cities
Loma Linda, California • Long Beach, California • Roseville, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03226392
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Andalusia, Alabama • Birmingham, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 26, 2026, 4:12 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

NCT01545440
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
70
States / cities
Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 26, 2026, 4:12 AM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 26, 2026, 4:12 AM EDT
Terminated No phase listed Observational

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

NCT04518722
View directory record Official record
Conditions
Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions
CT Scan, DXA Scan, Steroid Intake Questionnaire
Radiation · Other
Lead sponsor
University of Iowa
Other
Eligibility
25 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 26, 2026, 4:12 AM EDT